Pavan Bachireddy

Internal Medicine

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal: Journal of hematology & oncology

Published: April 17, 2026

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes.

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

ASXL1 truncating mutations drive leukemic resistance to T cell attack.

ASXL1 truncating mutations drive leukemic resistance to T cell attack.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2025

Mechanisms of immune escape and extramedullary tropism in leukemia cutis.

Mechanisms of immune escape and extramedullary tropism in leukemia cutis.

Journal: Blood

Published: March 12, 2025

Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy.

Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy.

Journal: Science immunology

Published: January 24, 2025

GPR56 in GVL: marker or mechanism?

GPR56 in GVL: marker or mechanism?

Journal: Blood

Published: March 28, 2024

Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy.

Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy.

Journal: bioRxiv : the preprint server for biology

Published: February 26, 2024

Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.

Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.

Journal: Cell reports

Published: August 09, 2023

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Journal: Blood

Published: September 08, 2022

ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.

ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.

Journal: Cancer cell

Published: July 14, 2022

Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case.

Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case.

Journal: Blood advances

Published: January 22, 2021

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.

Journal: Blood

Published: January 15, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026